CardieX Limited (ASX: $CDX) Supplementary Prospectus Update

CardieX Limited (ASX: $CDX) has issued a supplementary prospectus on 18 January 2024, supplementing the prospectus dated 19 December 2023. The purpose of this supplementary prospectus is to provide additional information to investors regarding the developments that have occurred since the lodgement of the prospectus with ASIC. Notably, the company is awaiting ASX's approval for the reinstatement of trading, subject to certain conditions, and has taken steps to satisfy these conditions.

Executive Commentary on ASX Trading Reinstatement and Underwriting Agreement

The Company has been diligently working towards meeting the conditions set by ASX for the reinstatement of trading. We have made significant progress in securing commitments from existing shareholders and new investors to mitigate the risk associated with the Entitlement Offer. Additionally, the underwriting agreement with C2 Ventures Pty Ltd provides further assurance in meeting ASX's conditions. We are confident in our ability to satisfy these conditions, subject to Shareholder approval of Tranche 2 of the Placement and the issue of the Quoted Options. It's important to note that ASX's decision to reinstate trading is discretionary, and they may impose additional conditions in the future.

Summary of ASX Announcement and Outlook

CardieX Limited (ASX: $CDX) has taken significant steps to satisfy ASX's conditions for the reinstatement of trading, including securing commitments from shareholders, underwriting the Entitlement Offer, and diligently working towards meeting the necessary requirements. The company anticipates that upon the completion of the Placement and Entitlement Offer, it will have sufficient working capital to carry out its stated objectives. The underwriting agreement with C2 Ventures Pty Ltd may result in an increase in their relevant interests in the company's shares, subject to certain exemptions. The company believes that the developments described in the supplementary prospectus are not materially adverse from the perspective of an investor in the Offers. CardieX Limited is looking forward to the reinstatement of trading, subject to the necessary approvals, and remains focused on achieving its corporate objectives.